State marijuana regulators tell congressional lawmakers that they need to investigate the lack of federal regulations for hemp-derived CBD-products, and also take into consideration other cannabinoids such as delta-8 THC which are emerging on the marketplace. They should also give an agency like Food and Drug Administration enhanced regulatory authority.
The Cannabis Regulators Association sent a letter to lawmakers on Friday in response to a request from House and Senate committees for expert opinion on CBD regulations last month. In the letter, they offered recommendations for creating a framework that would include all hemp-based cannabis cannabinoids. The submission was based on the collective experience of group members in overseeing state cannabis programs.
The scope of the investigation is one of the main concerns regulators raised with the House Energy & Commerce Committee and Senate Health, Education, Labor, and Pensions Committee.
The 2018 Farm Bill, which legalized hemp, also decontrolled other derivatives, such as delta-8 THC or THC-O acetate, that are intoxicating. CANNRA stated that Congress “effectively legalized cannabis federally without product regulation and called it hemp.” ‘”
Drug Enforcement Administration (DEA), has stated that it considers these cannabinoids to be illegal if they are synthetically produced, as is the common practice with delta-8 THC. However, despite limited enforcement of this law, the market for these products has thrived. The Drug Enforcement Administration (DEA) has said that it considers those cannabinoids illegal if they’re synthetically produced, as is common practice for delta-8 THC. However, the market for such products has flourished despite limited enforcement.
The letter states that “Hemp-derived product on the market can be consumed, applied topically or transmucosally or applied in other ways, such as by aerosolizing, inhaling or combusting, or applying transdermally.” “Many products and forms are beyond what would be permitted in state-regulated marijuana marketplaces.”
“A comprehensive approach to regulation that includes all hemp cannabinoid products is urgently required.” The regulators stated that a federal regulatory approach should have a wide focus and regulatory authority that addresses the products available today on the market as well as those that will be available in future. “A sole focus on CBD is not enough, partly because many CBD products also contain other cannabinoids that need to be regulated in order to ensure consumer safety and public welfare.”
FDA has been criticized by many lawmakers and hemp industry stakeholder for its refusal to adopt regulations for CBD. CANNRA, however, said that it agreed with the FDA that it lacks the authority necessary to develop the comprehensive framework necessary for a market as complex as this.
The letter states that “existing pathways do NOT address aerosolized products, inhaled products, or combustion products.” They also lack sufficient authorities to test, regulate packaging and labeling for products and modes of use, regulate additives and other ingredients that may pose a risk, or limit the appeal of products and their consumption by youth. The current state regulatory frameworks that apply to cannabinoids derived by marijuana go beyond the FDA’s pathways.
The regulators stated that “FDA requires specific authorities as well as defined, short deadlines to issue regulations.”
They also suggested that the agency coordinate with states and territories to ensure that rules don’t develop in isolation. While federal regulations are important, the states should be able “to enact regulation that extends beyond federal minimums in order to further protect their consumers and communities.”
The organization, which recently expanded its membership by including international regulators also stressed that “regulation does not mean recriminalization.”
“A regulatory agency has a responsibility to decide whether a product is safe to manufacture or consume and to establish the regulatory policies necessary to protect against any adverse effects. “A determination that a particular product is unfit for commercial use does not equate to criminalizing its use,” they stated. Enforcement actions in different states are often focused on civil penalties that increase over time or on the impact on licenses to discourage production of unapproved goods.
The 43-page Letter provides detailed answers to around two dozen specific questions listed by the committees in their request for more information on the issue. These include everything from the current CBD marketplace to challenges associated with the lack of marketing regulations, to packaging and labeling requirement.
CANNRA wasn’t the only group to respond to the call for input from Congress.
In a letter sent to the panel, the U.S. Hemp Roundtable’s general counsel, who recently testified before a House Subcommittee regarding FDA inaction in CBD, answered questions from that panel.
The hemp association , unlike CANNRA however, argued, that FDA’s claim that it lacks the proper authority to create a regulatory framework to regulate cannabinoid was “flawed” and Congress should order it to act. The hemp association also stated that adults should have access to semi-synthetic cannabis like delta-8 THC.
The American Trade Association for Cannabis and Hemp, (ATACH), also sent a response letter to the committees. It said that FDA should regulate CBD but “the real elephant is the unregulated intoxicating synthetic hemp intoxicants.”
Michael Bronstein, ATACH president, said: “Make no mistake – the wide definition of hemp in 2018 Farm Bill led to an explosion of unregulated products derived from hemp that are intoxicating.” CBD is used to make hemp-derived intoxicants, and these products often contain levels of THC that are higher than those found in legal state markets. These products have an unknown safety profile, are sold to consumers outside a regulated market, and are accessible to youth.
The association stated such products should instead be regulated by Alcohol and Tobacco Tax and Trade Bureau.
Cornbread Hemp, a CBD company based in Kentucky, also shared its perspective on this issue on Thursday. The executives of the company said that “the vacuum caused by the lack of FDA regulation has created a patchwork state laws that is bad for business and confuse consumers.”
The also said if Congress moves to implement regulations on cannabinoids they should reserve stricter rules for intoxicating substances while treating CBD that contains up to 0.3 per cent THC by weight as dietary supplement under the Dietary Supplement Health and Education Act.
Marijuana Moment tracks more than 1,000 cannabis and drug policy bills that have been introduced in state legislatures, and Congress. Patreon supporters who pledge at least $25/month gain access to our interactive charts, maps and hearing calendar.
Discover more about our marijuana bills tracker. Become a Patreon supporter to gain access.
—
James Comer, the chairman of the House Oversight Committee (R-KY), announced in April that the panel would launch an investigation into this matter and requested that FDA provide documents related to the decision not to regulate the cannabinoid. Before the FDA made its decision, Comer expressed his intention to address the lack of rules.
A report by the U.S. Department of Agriculture , released in April, shows that the hemp industry suffered a significant decline in 2022. And stakeholders blame the FDA for its refusal to regulate CBD products.
In March , bipartisan members of Congress re-filed two separate bills which are intended to regulate hemp derivatives such as CBD in food and beverage supplements.
Sens. Ron Wyden, Rand Paul (R.KY), Jeff Merkley and Earl Blumenauer (D.OR) filed separate legislation last month to remove the regulatory barriers FDA claims prevent it from allowing CBD sale.
The Hemp Access and Consumer Safety Act , which was introduced in the last Congress, but never advanced, would exempt hemp, hemp-derived CBD, or any substance containing other ingredients derived from hemp from federal restrictions while allowing officials to implement labeling and packing rules.
The FDA announced that it would not be regulating CBD just days after released its finalized guidance which focuses on the development of cannabis-based medicines and details the process as well as unique considerations that scientists should take into account when it comes hemp and marijuana.
released the first-ever guidelines on developing psychedelic medicine. It is also actively working on reviewing the federal scheduling for marijuana, as per a directive given by President Joe Biden in 2013.
A GOP congressman says he’ll vote for legal marijuana on the Ohio ballot, as Governor calls the reform a’real mistake’
Photo by Kimzy Nanny.
The first time Marijuana moment published the post State Marijuana regulators tell Congress to focus on more than CBD by regulating other cannabinoids like Delta-8 THC.
